HORSHAM, Pa., May 28 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that data related to several compounds will be presented at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla., from May 29 to June 2, 2009. The studies were sponsored by Centocor Ortho Biotech Products, L.P. or its research partner, Ortho Biotech Oncology Research and Development, a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
"We are pleased that ASCO has accepted these data for presentation at their annual meeting," said Thomas Schaible, Vice President, Medical Affairs, Centocor Ortho Biotech. "Through our ongoing investigation of key clinical compounds, Centocor Ortho Biotech is committed to advancing the understanding of the therapeutic options it offers to patients fighting cancer."
Data from the following studies have been selected for presentation and posters:
- Relationship of rapid M protein reduction to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma (MM) (Abstract 8591) General Poster Session, Saturday May 30, 8:00 am to 12:00 pm, Level 2, West Hall C
Authors: J. J. Shah, A. Londhe, K. C. Lantz, C. Lowery, R. Z. Orlowski; University of Texas M. D. Anderson Cancer Center, Houston, TX; Centocor Ortho Biotech Services LLC, Horsham, PA
- Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone (Abstract 5550)
General Poster Session, Sunday May 31, 2:00 pm to 6:00 pm, Level 2, West Hall C
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1
|SOURCE Centocor Ortho Biotech Products, L.P.|
Copyright©2009 PR Newswire.
All rights reserved
. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor2
. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA3
. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 20114
. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis5
. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product6
. GeneNews provides Centocor access to its osteoarthritis program7
. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)8
. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients9
. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases10
. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product11
. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System